INCY is Incyte Genomics Inc (Industrials) — a non-dividend-paying stock. Trading at $116.93. Market cap: $23.70B. Capital Quality Rank: 100/100 — Market alpha.
Stock snapshot
| Price | $116.93 |
| Market cap | $23.70B |
| Sector | Industrials |
| Exchange | XNAS |
| Pays dividend | No |
Capital Quality & fundamentals
DiviDrip's Capital Analytics engine ranks every non-dividend stock 1-100 on a 4-factor composite (Shareholder Yield 30%, Cash-Flow ROI 25%, Operating Momentum 25%, Tail-Risk 20%) — sector-neutralized so a biotech isn't penalized for negative earnings the way a utility would be.
| Capital Quality Rank (1-100) | 100 / 100 · Market alpha |
| ROIC (TTM) | 57.0% |
| Revenue CAGR (3y) | 14.8% |
| Shareholder buyback yield | 4.90% |
| Altman Z-score zone | Safe |
Valuation, price chart & technicals
Valuation Multiples— the whole story at a glance
vs 779 Industrials peers (median)PEG colour: ≤ 1.0 cheap · 1–2 fair · > 2 rich. Lower = the stock's price is rising slower than its growth.
Price Chart
+32.78%Technicals
About INCY
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Related non-dividend companies
Other non-dividend stocks investors research alongside INCY. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is INCY's current stock price?
INCY (Incyte Genomics Inc) is currently trading at $116.93.
Does INCY pay a dividend?
INCY (Incyte Genomics Inc) does not currently pay a regular dividend.
What is INCY's Capital Quality Rank?
INCY has a Capital Quality Rank of 100/100 — Market alpha. This score blends ROIC, revenue growth, buybacks, and balance-sheet health.
Track INCY in DiviDrip
Add INCY to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search INCY and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-10-23. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.